Current reports
Current Report No. 20/2026 – Positive Notified Body Opinion for the Pen Injector Used in the Development of Celon Pharma’s Semaglutide Product
Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) – Inside Information With reference to Current Report No. 17/2026 dated 20 August 2026 concerning the positive results of the bioequivalence study of a medicinal product containing semaglutide, the Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it has received a positiveRead more »
Current Report No. 17/2026 – Positive Results of the Bioequivalence Study of Celon Semaglutide (Reduzek)
Legal basis: Article 17(1) of the Market Abuse Regulation (MAR) – Inside InformationDate and time: 20 August 2026, 11:33 The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that the Company has obtained positive results from a bioequivalence study of its semaglutide-containing medicinal product, Reduzek, currently under development by the Company. The objectiveRead more »
Current report no 9/2026 – Execution of an Agreement with Pharmalink for the Commercialization of Reduzek (semaglutide) in Selected Gulf Countries
Legal Basis: Article 17(1) of the MAR Regulation – Inside Information Report Content: The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on 8 June 2026 it entered into a License and Supply Agreement with Pharmalink Drug Store L.L.C. (“Pharmalink”) for the commercialization of Celon Pharma’s Reduzek (semaglutide products) in multi-dose pensRead more »
Current Report No. 8/2026 – Allocation of Series A Subscription Warrants to Eligible Participants under the Management Incentive Program
Legal basis: Article 17(1) of the MAR Regulation – Inside Information, 1:52 p.m. Report content: The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it has adopted a resolution regarding the allocation of a total of 55,000 Series A subscription warrants (the “Warrants”) under the Management Incentive Program for the year 2026.Read more »
Current Report No. 7/2026 – Notice of Convening the Annual General Meeting of Celon Pharma S.A. on June 24, 2026, Together with Draft Resolutions
Legal basis: Article 56(1)(2) of the Public Offering Act – Current and Periodic Information Report content: The Management Board of Celon Pharma S.A. (the “Company”), acting pursuant to Articles 395 §1, 399 §1, 402(1) and 402(2) of the Polish Commercial Companies Code (the “CCC”), hereby convenes the Annual General Meeting to be held on JuneRead more »
Current Report No. 6/2026 – Four Celon Pharma S.A. Projects Selected for Funding under a Competition Announced by the Medical Research Agency
Legal basis: Article 17(1) of the MAR Regulation – Inside Information, 7:11 p.m. The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on May 5, 2026, it was informed that four of the Company’s applications for project funding (the “Projects”), submitted under the Medical Research Agency’s (Agencja Badań Medycznych, “ABM”) Competition forRead more »
Current report 5/2026 – Execution of Amendments to Agreements Concerning Cooperation with Tang Capital
Legal basis: Article 17(1) MAR – inside information, 17:04 Report content: With reference to current report No. 4/2024 dated 22 May 2024 regarding the execution by Celon Pharma S.A. (“Company”, “Celon”) and Tang Capital Management, LLC (“Tang Capital”) of agreements concerning cooperation aimed at establishing Novohale Therapeutics, LLC (“Novohale”) and the further development of theRead more »
Current Report No. 4/2026 – Execution of a Financing Agreement by the Issuer’s Subsidiary with the European Bank for Reconstruction and Development
Date of publication: March 9, 2026, 12:06 p.m. Legal basis: Article 17(1) of the MAR Regulation – Inside Information Report content: Further to Current Report No. 13/2025 dated August 4, 2025, regarding the agreement with the European Bank for Reconstruction and Development (“EBRD”) on the principal terms and conditions of financing to be granted toRead more »
Current Report No. 3/2026 – Resignation and Appointment of a Management Board Member of Celon Pharma S.A.
Legal basis: Article 56(1)(2) of the Public Offering Act – Current and Periodic Information Report content: The Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on February 27, 2026, Mr. Bartosz Szałek submitted his resignation from the positions of Member of the Management Board and Chief Financial Officer of the Company, effectiveRead more »